Aspire Biopharma Holdings, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
1.30M
on 2026-06-30, from 23K on 2024-12-31 10-Q ↗
Earlier counts are adjusted for the 1-for-30 reverse split; each bar's tip shows the count as filed.
a raise that quarter, at its price
Newest
None
No S-3 or F-3 shelf on file in the last 30 months.
9 of its filings are not read yet.
Warrants
The 10-Q filed 2026-08-13 is not read yet.
Cash
6.8 quarters
$12.2M on 2026-06-30 ÷ $1.8M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-02-06 | Private placement | 13,750 | not read | $11.0M | 8-K ↗ |
Also on file: $3.8M convertible notes, 2025-02-17 8-K ↗ · $9.7M notes, 2025-08-19 8-K ↗ · $2.2M notes, 2026-01-26 8-K ↗ · a 1-for-30 reverse split, 2026-05-11 8-K ↗ · $3.8M convertible notes, 2026-08-06 8-K ↗